Consensus Molecular Subtyping of Colorectal Cancer Demonstrates Cetuximab Benefit in Right sided CMS2 Tumors, and Pembrolizumab Benefit in MSS CMS1 Tumors

Authors:

John Paul Shen, Joanne Xiu, Theodore Nicolaides, Jian Zhang, Saikat Chowdhury, W. Michael Korn, Kelsey Poorman, Heinz-Josef Lenz, John Marshall, Matthew Oberley, George Sledge, David Spetzler, Scott Kopetz

Conclusions

  • A Whole-Transcriptome-Sequencing based CMS classifier allows for investigation in a large real-world clinic-genomic database.
  • We found that MSS CMS1 CRC’s may derive benefit from immunotherapy.
  • Additionally, CMS2 subgroup of right-sided tumors may derive benefit from cetuximab.
  • Routine CMS subgrouping of CRC provides important treatment associations that should be further investigated.
Download Publication